Gossamer Bio's pulmonary arterial hypertension investment case depends on FDA review converting the seralutinib NDA into an approvable product, with regulatory acceptance and approval the decisive conditions. The pivotal PROSERA study's estimated Week 24 treatment effect was +13.3 meters, with p=0.0320, missing the prespecified primary-endpoint threshold of α=0.025. The FDA will decide whether to accept the NDA for filing after an initial review, then determine the acceptability of the application's elements during review of the complete NDA.
Gossamer Bio and Chiesi agreed to terminate their Collaboration and License Agreement, and Gossamer reacquired worldwide development and commercial rights to seralutinib. That termination dissolved the prior U.S. 50/50 profit share and returned ex-U.S. rights to Gossamer.
Business Cycle
Competitive Advantages
Competitive Disadvantages
Competitive Landscape
Customer Acquisition
Porter's Five Forces
Fundraising Environment
Growth Drivers
Market Outlook
Pricing Strategy
Risk Factors
SWOT Analysis
Unit Economics
Product Overview
Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company developing the investigational drug seralutinib for pulmonary arterial hypertension and interstitial lung disease.